Supriya Lifescience Ltd. IPO

Supriya Lifescience Ltd.

IPO Listing Details

Listed On

BSE & NSE

Listed On

Issue Price

₹274

Issue Price

Listing Price

₹425

Listing Price

Listing Gains

+₹151.00 (+55.11%)

Listing Gains

IPO Details

Bidding Dates

16 Dec - 20 Dec '21

Bidding Dates

Min. Investment

₹14,310

Min. Investment

Lot Size

54.00

Lot Size

Price Range

₹265 - ₹274

Price Range

Issue Size

677 Cr

Issue Size

IPO Doc

(D)RHP PDF  

(D)RHP PDF

Subscription Rate - Supriya Lifescience Ltd. IPO

  • Retail Individual Investor
    56.01x
  • Non-Institutional Investor
    161.22x
  • Qualified Institutional Buyers
    31.83x
  • Employees
    NA


About Supriya Lifescience Ltd. IPO

With an emphasis on research and development, Supriya LifeSciences is one of the leading Indian manufacturers and suppliers of Active Pharmaceutical Ingredients. It offers speciality offerings of 38 APIs centered on various categories such as antihistamine, analgesic, anesthetic, vitamin, anti-asthmatic, and antiallergic by the end of October 21.

They have consistently been the top exporter of Chlorpheniramine Maletas and Ketamine Hydrochloride from India, accounting for 45 to 50 percent and 60 to 65 percent of total API exports from India from 2017 to 2021, respectively.



In terms of volume, Supriya LifeSciences is the largest exporter of salbutamol sulfate in India, accounting for 31% of API exports from India in 2021. Its pharmaceutical business is divided into domestic and international sales. Its products are sold to 1,296 clients in 86 countries through 346 distributors.

Why should you invest in Supriya Lifescience Ltd. IPO?

Here are a few advantages to investing with this company.

  • The firm is one of India's most well-known API manufacturers.

  • Its products are exported to over 86 countries due to its specific and diverse market. Due to its de-risked business strategy, the company has superior research and development capabilities as well as a good financial track record.

  • In the last three years, the company has experienced strong revenue growth.

  • In the last three years, the company's margins have dramatically improved.

Financial Snapshot - Supriya LifeSciences IPO

The company’s entire assets, revenues, and profits for the last three years are represented here.

  • Details
    2019 (in millions)
    2020 (in millions)
    2021 (in millions)
    September, 2021 (in millions)
  • Total Assets
    2,530.5
    3,364.0
    4,458.2
    5,041.0
  • Revenues
    2,858.6
    3,227.1
    3,962.2
    2,300.6
  • PAT
    394.2
    733.7
    1,238.3
    659.6
  • Profit
    13.79%
    22.74%
    31.25%
    28.67%

Important Dates - Supriya LifeSciences IPO

The following are some key dates to remember for Supriya LifeSciences' initial public offering:

  • IPO Start Date
    16 Dec 2021
  • IPO End Date
    20 Dec 2021
  • Allotment Date
    23 Dec 2021
  • Initiation of Refunds
    24 Dec 2021
  • Credit of Shares to Demat Account Date
    27 Dec 2021
  • IPO Listing Date
    28 Dec 2021


SWOT Analysis - Supriya Lifescience Ltd. IPO

Strengths:

The company has a large scale and a leadership position in the industry's main and specialty products. The firm focuses on advanced manufacturing as well as research and development. Supriya Lifescience has a professional management team with extensive expertise and trained operational people.

Weaknesses:

A complicated set of rules governs their industry. Any production or quality control problems could tarnish the reputation and expose the company to legal action or other liabilities, affecting their financial performance. The sale of specific products accounts for a significant portion of their earnings.

Opportunities:

The corporation uses an integrated business model. With a presence in around 86 countries, it is a global player.

Threats:

Their lenders have imposed some restrictions on them as part of their financial arrangements. Their inability to compete successfully in the pharmaceutical sector could hurt their firm. Existing technologies may become obsolete as a result of technological breakthroughs, necessitating major capital inputs.


Competitive Analysis - Supriya Lifescience Ltd. IPO

  • A large corporation with a leadership position in important and specialized products.

  • It has a business model that is backward integrated.

  • Its revenues are geographically diverse, with a global presence in 86 countries.

  • Advanced manufacturing and research and development capabilities are available at the company.

  • Due to its de-risked business style, the company produces consistently solid financial results.

  • It has a senior management team with years of experience and qualified operational personnel.



How to apply for Supriya Lifescience Ltd. IPO?

You can apply for the Supriya Lifescience Ltd. IPO in these ways:

UPI
Link your personal bank A/C to a trusted UPI ID and map it with your TradeSmart account. Now, proceed further to book your IPO. On acceptance of the mandate, the bid amount will get blocked in your bank account Learn more.

Demat Account

1. If you are an Existing TradeSmart demat account holder and wish to apply for an Supriya Lifescience Ltd. click here.
2. If you don't have a TradeSmart Account? Sign up.

Looking to invest in an IPO?

Open Demat Account at lowest Brokerage

Frequently Asked Questions (FAQs) - Supriya Lifescience Ltd. IPO

When will Supriya Lifescience's initial public offering (IPO) begin?

The Supriya Lifescience initial public offering (IPO) will begin on December 16, 2021, and end on December 20, 2021.

What is the Supriya Lifescience IPO lot size?

The minimum order quantity for the Supriya Lifescience IPO is 54 shares, and the market lot size is 13.

What percentage of the IPO is allotted to each investment group?

QIB - 75% of the available shares. Retail - 10% of the available share must be sold to the general public. NII / HNI - 15% of the offered shares for NII / HNI.

What is the minimum subscription amount for this IPO?

Investors must apply for 54 shares at the lowest price range of INR 265 per share, which equals INR 14,310. Similarly, the minimum amount to be applied on the upper pricing band is INR 274 = INR 14,796.

Is it advantageous or disadvantageous in terms of investment?

Investing in a firm with a solid financial track record is usually a good idea. In the last 3.5 years, this company has had significant revenue growth. In recent years, the company's profits have increased significantly.

What is the current status of Supriya LifeScience's IPO GMP?

GMP stands for the premium at which shares trade in the offline market. Because it is an unorganised market, this is merely an indicator of the IPO price. Supriya LifeScience IPO GMP is not available because no trades are currently taking place.

Related

Lowest Brokerage Ever Trade @15 Per Order
Download the app now

Scan below QR Code
to download App

TradeSmart Demat Account
Open Demat Account